This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cota, J.
Right arrow Articles by Wiederhold, N. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cota, J.
Right arrow Articles by Wiederhold, N. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2006, p. 3926-3928, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00538-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility{triangledown}

Jason Cota,1,2 Michael Carden,2 John R. Graybill,2 Laura K. Najvar,2 David S. Burgess,1,2 and Nathan P. Wiederhold1,2*

The University of Texas at Austin College of Pharmacy, Austin, Texas,1 The University of Texas Health Science Center at San Antonio, San Antonio, Texas2

Received 1 May 2006/ Returned for modification 19 June 2006/ Accepted 14 August 2006


arrow
ABSTRACT
 
The activities of anidulafungin and caspofungin against Candida glabrata were evaluated. MICs, 50% inhibitory concentrations (IC50 values), and IC90 values for anidulafungin were lower than those for caspofungin for 16 of 18 strains tested. Anidulafungin has potent in vitro activity against C. glabrata that is maintained against isolates with elevated caspofungin MICs.


arrow
TEXT
 
Infections caused by Candida glabrata have been reported to be increasing in frequency (19, 30) and are associated with high mortality rates for the elderly, immunocompromised patients, and patients in intensive care units (2, 11, 27). Treatment may be complicated by the variable susceptibility of C. glabrata to fluconazole and by reduced response rates to other azole antifungals in breakthrough infections (2, 11, 22, 26, 29).

The echinocandins have emerged as an effective treatment strategy for invasive candidiasis. Although susceptibility breakpoints are not currently established, broth microdilution studies have demonstrated relatively good activity for each member of this class against Candida isolates, including non-C. albicans species (13, 28). However, case reports describing clinical failures of caspofungin associated with reduced in vitro activity against C. albicans, C. glabrata, and C. krusei have begun to emerge (6, 7, 9, 10, 14, 21). It is currently unknown if other echinocandins would maintain potency at clinically relevant exposures in the face of diminished caspofungin activity. The objective of this study was to compare the in vitro activities and pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates over a range of clinically achievable concentrations.

(Part of this work was presented previously [N. P. Wiederhold, J. R. Graybill, L. K. Najvar, and D. S. Burgess, Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-2160, 2005].)

Eighteen Candida glabrata isolates from the University of Texas Health Science Center at San Antonio were tested. Stock solutions of anidulafungin (Vicuron Pharmaceuticals, King of Prussia, PA) and caspofungin (Merck & Co., Inc., Whitehouse Station, NJ) were prepared by dissolving drug powders in dimethyl sulfoxide and water, respectively.

Microdilution broth susceptibility testing was performed in duplicate according to the CLSI M27-A2 method in RPMI growth medium buffered with 0.165 M 4-morpholinepropanesulfonic acid (15). The MIC2 was defined as the lowest concentration of anidulafungin or caspofungin that caused a significant decrease in turbidity (≥50%) compared to that of the growth control, and the MIC0 was defined as the lowest concentration resulting in no visual growth. The minimum fungicidal concentration (MFC) was measured as previously described (5).

The 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) colorimetric assay was performed in triplicate as previously reported (12). Final anidulafungin concentrations ranged from 0.015 to 32 µg/ml, and those of caspofungin ranged from 0.06 to 128 µg/ml. The absorbance was read at 492 nm, and readings were converted to percent absorbance, with values for growth control wells set at 100% and those for medium control wells set at 0%. XTT reduction assay data were fit to a four-parameter inhibitory sigmoid model, using computer curve fitting software (Prism 4; GraphPad Software, Inc., San Diego, CA), to derive 50% inhibitory concentration (IC50) and IC90 values. The goodness of fit for each isolate/drug was assessed by the R2 value and the standard error of the IC50 value. The IC50 and IC90 values were not determined if minimal or no reduction in formazan absorbance was observed with increasing drug concentrations.

Time-kill studies were performed in duplicate on isolates with caspofungin MICs of ≥8 µg/ml, using previously described methods (8). The anidulafungin and caspofungin concentrations tested were 0.5, 1.0, 4.0, 8.0, and 16 µg/ml. These are within the range achieved clinically for both agents (3, 4, 25). Fungicidal activity was defined as a ≥3-log10 (99.9%) reduction in CFU from the starting inoculum.

Anidulafungin MICs ranged from 0.125 to 4 µg/ml and were at least two dilutions lower than those of caspofungin (range, 1 to 64 µg/ml) for 16 of the 18 isolates tested, including the three isolates with elevated caspofungin MICs (Table 1). Similarly, the MFCs for anidulafungin (range, 0.25 to 8 µg/ml) were ≥2 dilutions lower than those of caspofungin (1 to ≥128 µg/ml) for 14 of the 18 isolates tested. Anidulafungin remained fungicidal against the three strains with elevated caspofungin MFCs (≥64 µg/ml).


View this table:
[in this window]
[in a new window]
  		TABLE 1. MIC, MFC, IC50, and IC90 values for anidulafungin and caspofungin against C. glabrata isolates

The potency of anidulafungin was greater than that of caspofungin, as evidenced by a lower IC50 value for each strain evaluated (Table 1). Similarly, the IC90 values for anidulafungin were also lower than those for caspofungin against all isolates. Against the isolates with caspofungin MICs of ≥8 µg/ml, only the highest concentration of caspofungin tested (128 µg/ml) resulted in a >90% reduction in viability, while anidulafungin maintained its potency (IC50 range, 0.17 to 2.4 µg/ml; IC90 range, 3.6 to 7.8 µg/ml).

These results are supported by data from time-kill studies (Fig. 1). Against C. glabrata isolate 16, anidulafungin at 1 µg/ml resulted in a >3-log10 CFU/ml decrease in the starting inoculum at 24 h, compared to a 0.43-log10 CFU/ml reduction for caspofungin at 16 µg/ml. Anidulafungin at 4 µg/ml was fungicidal against isolate 18, in contrast to the 0.54-log10 CFU/ml increase observed with caspofungin at 16 µg/ml. Minimal activity was also observed for caspofungin against C. glabrata isolate 17 at the highest concentration tested (0.65-log10 increase in CFU/ml at 16 µg/ml). Although anidulafungin was not fungicidal against this isolate, concentrations of ≥4 µg/ml did result in reductions in colony counts (≥1.74-log10 CFU/ml decrease).


Figure 1
View larger version (36K):
[in this window]
[in a new window]
  		FIG. 1. Dose-response curves (A, D, and G) and time-kill plots (B, C, E, F, H, and I) for anidulafungin and caspofungin against C. glabrata isolates with caspofungin MICs of ≥8 µg/ml. (A, B, and C) C. glabrata isolate 16; (D, E, and F) C. glabrata isolate 17; (G, H, and I) C. glabrata isolate 18. Symbols in dose-response curves (A, D, and G) show means ± standard errors for experiments performed in triplicate with anidulafungin (•) and caspofungin ({circ}). Curves were generated by fitting XTT data to a four-parameter inhibitory sigmoid model. Symbols in time-kill plots (B, C, E, F, H, and I) show the mean values for log10 CFU/ml versus time for anidulafungin (B, E, and H) and caspofungin (C, F, and I) against C. glabrata isolates with caspofungin MICs of ≥8 µg/ml. Drug concentrations: {blacksquare}, control; {blacktriangleup}, 0.5 µg/ml; {blacklozenge}, 1 µg/ml; •, 4 µg/ml; {blacktriangledown}, 8 µg/ml; and *, 16 µg/ml. Symbols represent the means ± standard errors for experiments performed in duplicate for each drug. Emax values represent maximum log10 reductions in CFU/ml for anidulafungin and caspofungin against each isolate at 24 h.

Surveillance studies have reported relatively good activities for the echinocandins compared to other antifungals against Candida species, including non-C. albicans and fluconazole-resistant isolates (1, 5, 16, 17, 24). Against the isolates of C. glabrata tested for this study, anidulafungin had greater in vitro potency than did caspofungin, as evidenced by lower MIC and MFC values. The enhanced potency of anidulafungin against C. glabrata isolates is also supported by pharmacodynamic data from XTT and time-kill assays and was maintained against C. glabrata isolates with elevated caspofungin MICs.

While no strong correlation exists between susceptibility data and clinical success in the treatment of invasive fungal infections, in vitro and in vivo data suggest that antifungal MICs may be predictive of responses to therapy (7, 9). Furthermore, antifungal resistance is associated with clinical failure (9, 18, 20, 23). Recent reports suggested that this may also be true for caspofungin in the setting of elevated MICs (6, 7, 9, 10, 14, 21). Due to the difficulty in treating invasive candidiasis that is unresponsive to prior therapy, further studies investigating the utility of anidulafungin in this setting are warranted.


arrow
ACKNOWLEDGMENTS
 
This work was funded in part by a grant from Vicuron Pharmaceuticals to J.R.G.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: University of Texas at Austin College of Pharmacy, UTHSCSA, Clinical Pharmacy, MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229. Phone: (210) 567-8340. Fax: (210) 567-8328. E-mail: wiederholdn{at}uthscsa.edu. Back

{triangledown} Published ahead of print on 28 August 2006. Back


arrow
REFERENCES
 
    1
  1. Arevalo, M. P., A. J. Carrillo-Munoz, J. Salgado, D. Cardenes, S. Brio, G. Quindos, and A. Espinel-Ingroff. 2003. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother. 51:163-166.[Abstract/Free Full Text]
    2. 2
  2. Bodey, G. P., M. Mardani, H. A. Hanna, M. Boktour, J. Abbas, E. Girgawy, R. Y. Hachem, D. P. Kontoyiannis, and I. I. Raad. 2002. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. 112:380-385.[CrossRef][Medline]
    3. 3
  3. Dowell, J. A., W. Knebel, T. Ludden, M. Stogniew, D. Krause, and T. Henkel. 2004. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44:590-598.[Abstract/Free Full Text]
    4. 4
  4. Dowell, J. A., M. Stogniew, D. Krause, T. Henkel, and I. E. Weston. 2005. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J. Clin. Pharmacol. 45:227-233.[Abstract/Free Full Text]
    5. 5
  5. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.[Abstract/Free Full Text]
    6. 6
  6. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.[Abstract/Free Full Text]
    7. 7
  7. Hernandez, S., J. L. Lopez-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.[Abstract/Free Full Text]
    8. 8
  8. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.[Abstract/Free Full Text]
    9. 9
  9. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.[CrossRef][Medline]
    10. 10
  10. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.[Abstract/Free Full Text]
    11. 11
  11. Malani, A., J. Hmoud, L. Chiu, P. L. Carver, A. Bielaczyc, and C. A. Kauffman. 2005. Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. 41:975-981.[CrossRef][Medline]
    12. 12
  12. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, P. J. Donnelly, and P. E. Verweij. 2001. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263.[Abstract/Free Full Text]
    13. 13
  13. Messer, S. A., J. T. Kirby, H. S. Sader, T. R. Fritsche, and R. N. Jones. 2004. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54:1051-1056.[Abstract/Free Full Text]
    14. 14
  14. Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26:877-880.[CrossRef][Medline]
    15. 15
  15. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    16. 16
  16. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.[Abstract/Free Full Text]
    17. 17
  17. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.[Abstract/Free Full Text]
    18. 18
  18. Panackal, A. A., J. L. Gribskov, J. F. Staab, K. A. Kirby, M. Rinaldi, and K. A. Marr. 2006. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44:1740-1743.[Abstract/Free Full Text]
    19. 19
  19. Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, and W. E. Dismukes. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.[CrossRef][Medline]
    20. 20
  20. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.[CrossRef][Medline]
    21. 21
  21. Pelletier, R., I. Alarie, R. Lagace, and T. J. Walsh. 2005. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med. Mycol. 43:559-564.[CrossRef][Medline]
    22. 22
  22. Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.[CrossRef][Medline]
    23. 23
  23. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.[CrossRef][Medline]
    24. 24
  24. Roling, E. E., M. E. Klepser, A. Wasson, R. E. Lewis, E. J. Ernst, and M. A. Pfaller. 2002. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. 43:13-17.
    25. 25
  25. Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L. Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.[Abstract/Free Full Text]
    26. 26
  26. vanden Bossche, H., P. Marichal, F. C. Odds, L. Le Jeune, and M. C. Coene. 1992. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36:2602-2610.[Abstract/Free Full Text]
    27. 27
  27. Viscoli, C., C. Girmenia, A. Marinus, L. Collette, P. Martino, B. Vandercam, C. Doyen, B. Lebeau, D. Spence, V. Krcmery, B. De Pauw, and F. Meunier. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1079.[Medline]
    28. 28
  28. Wiederhold, N. P., and R. E. Lewis. 2003. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs 12:1313-1333.[CrossRef][Medline]
    29. 29
  29. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.[Abstract/Free Full Text]
    30. 30
  30. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, November 2006, p. 3926-3928, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00538-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., Bohrmueller, J. (2008). In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 3497-3503 [Abstract] [Full Text]  
  • Thompson, G. R. III, Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S. II, Patterson, T. F. (2008). Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection. Antimicrob. Agents Chemother. 52: 3783-3785 [Abstract] [Full Text]  
  • Cota, J. M., Grabinski, J. L., Talbert, R. L., Burgess, D. S., Rogers, P. D., Edlind, T. D., Wiederhold, N. P. (2008). Increases in SLT2 Expression and Chitin Content Are Associated with Incomplete Killing of Candida glabrata by Caspofungin. Antimicrob. Agents Chemother. 52: 1144-1146 [Abstract] [Full Text]  
  • Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., Hou, J. (2008). In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 539-550 [Abstract] [Full Text]  
  • Wiederhold, N. P., Najvar, L. K., Bocanegra, R., Molina, D., Olivo, M., Graybill, J. R. (2007). In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera. Antimicrob. Agents Chemother. 51: 1616-1620 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cota, J.
Right arrow Articles by Wiederhold, N. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cota, J.
Right arrow Articles by Wiederhold, N. P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»